Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 8/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Menaquinone 7 SCHEMBL15438185 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL10055449 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL14164356 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL8709976 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menatetrenone SCHEMBL571912 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL10054546 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menatetrenone SCHEMBL8703544 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL571907 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| Menaquinone 6 SCHEMBL244452 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT | |
| SCHEMBL14164358 | 1.00 | PTGS1 (1.00) | PTGS1PDE4ASNCAPDE3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177457-A1 | SUPPLEMENT COMPOSITION FOR CONSUMPTION BY INDIVIDUALS BEING ADMINISTERED A GLP-1 AGONIST | Food Sciences Corp. | 2025-06-05 | — | — | US | claimed |
| US-12037576-B2 | Recombinant Bacillus subtilis for increasing yield of menaquinone 7 and application thereof | NANTONG LICHENG BIOLOGICAL ENGINEERING CO. LTD (CN) | 2024-07-16 | — | — | US | claimed |
| WO-2024144737-A2 | A FOOD SUPPLEMENT WITH PROBIOTIC MICROORGANISMS AND A MICROENCAPSULATED FOOD SUPPLEMENT | CHIVALRIC REGULUS BIYOTEKNOLOJI ANONIM SIRKETI (TR) | 2024-07-04 | — | — | WO | claimed |
| WO-2023150533-A1 | MICROORGANISMS AND METHODS FOR PRODUCING MENAQUINONE-7 | CONAGEN INC. (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230009798-A1 | SILICONE IMPLANT ADJUNCT FORMULATIONS AND METHODS OF USE | SUSSE KAYTE R (US) | 2023-01-12 | — | — | US | claimed |
| US-20220160651-A1 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K | NATTOPHARMA AS (NO) | 2022-05-26 | — | — | US | claimed |
| CN-104458990-B | Method for measuring content of vitamin K2 (MK-7) | 江苏艾兰得营养品有限公司 | 2017-01-18 | — | — | CN | claimed |
| CN-104458990-A | Method for measuring content of vitamin K2 (MK-7) | JIANGSU ALAND NOURISHMENT CO LTD | 2015-03-25 | — | — | CN | claimed |
| WO-2014131084-A1 | FERMENTATION AND IN SITU EXTRACTION OF MENAQUINONES DURING MICROBIAL CULTURE | THE UNIVERSITY OF SYDNEY (AU) | 2014-09-04 | — | — | WO | claimed |
| EP-1675580-A1 | NATURAL MENAQUINONE 7 COMPOSITIONS | Natural ASA (NO) | 2006-07-05 | — | — | EP | claimed |
| US-20050123603-A1 | Natural menaquinone 7 compositions | NATURAL ASA (NO) | 2005-06-09 | — | — | US | claimed |
| WO-2005030190-A1 | NATURAL MENAQUINONE 7 COMPOSITIONS | NATURAL ASA (US) | 2005-04-07 | — | — | WO | claimed |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | LONZA SALES AG (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4054348-B1 | PARTICLES CONTAINING A LIPID MATRIX CORE AND ACTIVE INGREDIENT | LONZA SALES AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-12465075-B2 | Particles containing a lipid matrix core and active ingredient | LONZA SALES AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-12433854-B2 | Methods and compositions for preventing or treating calciphylaxis | Epizon Pharma, Inc. (US) | 2025-10-07 | — | — | US | disclosed |
| US-6207652-B1 | INDUCING APOPTOSIS BY USING SULFATED-FUCOSE-CONTAINING POLYSACCHARIDES AND/OR DEGRADATION PRODUCTS THEREOF AS THE ACTIVE INGREDIENT | TAKARA SHUZO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| EP-0919237-A1 | APOPTOSIS INDUCERS | TAKARA SHUZO CO. LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
| CN-1209749-A | apoptosis inducer | TAKARA SHUZO CO (JP) | 1999-03-03 | — | — | CN | disclosed |
| CN-1183101-A | Sugar compounds | TAKARA SHUZO CO (JP) | 1998-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160651-A1 | RAPIDLY IMPROVING ENDOTHELIAL FUNCTION, REDUCING ARTERIAL STIFFNESS AND REVERSING CALCIFICATION OF BLOOD VESSELS BY ADMINISTERING VITAMIN K | PROC, VDR, MYLK | PTGS1 157/4885PDE4A 126/4885SNCA 4876/4885 |
| US-20050123603-A1 | Natural menaquinone 7 compositions | NQO1, SIRT7, NAA15 | PTGS1 3189/4885PDE4A 3080/4885SNCA 3098/4885 |
| US-20260123660-A1 | Particles Containing a Lipid Matrix Core and Active Ingredient | AUP1, MGLL, MBOAT4 | PTGS1 2932/4885PDE4A 2722/4885SNCA 266/4885 |
| US-12433854-B2 | Methods and compositions for preventing or treating calciphylaxis | PCSK7, PCSK9, PTH1R | PTGS1 1248/4885PDE4A 1304/4885SNCA 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.